567 related articles for article (PubMed ID: 22356303)
21. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
Yedurkar P; Dhiman MK; Petkar K; Sawant K
J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
[TBL] [Abstract][Full Text] [Related]
22. Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation.
Liu D; Yu S; Zhu Z; Lyu C; Bai C; Ge H; Yang X; Pan W
Int J Pharm; 2014 Nov; 475(1-2):496-503. PubMed ID: 25219321
[TBL] [Abstract][Full Text] [Related]
23. Enhancement of skin permeation of bufalin by limonene via reservoir type transdermal patch: formulation design and biopharmaceutical evaluation.
Yang Z; Teng Y; Wang H; Hou H
Int J Pharm; 2013 Apr; 447(1-2):231-40. PubMed ID: 23467076
[TBL] [Abstract][Full Text] [Related]
24. Design and Evaluation of Transdermal Patches of Timolol Maleate.
Panchayya Hiremath SS; Reddy JJ; Jamakandi VG
Curr Drug Deliv; 2018; 15(5):658-663. PubMed ID: 28969565
[TBL] [Abstract][Full Text] [Related]
25. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
Singh B; Singh R; Bandyopadhyay S; Kapil R; Garg B
Colloids Surf B Biointerfaces; 2013 Jan; 101():465-74. PubMed ID: 23010056
[TBL] [Abstract][Full Text] [Related]
26. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
Thimmasetty J; Pandey G; Babu P
Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
[TBL] [Abstract][Full Text] [Related]
27. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement.
Sanjula B; Shah FM; Javed A; Alka A
J Drug Target; 2009 Apr; 17(3):249-56. PubMed ID: 19255893
[TBL] [Abstract][Full Text] [Related]
28. In vitro permeation of carvedilol through porcine skin: effect of vehicles and penetration enhancers.
Gannu R; Vishnu YV; Kishan V; Rao YM
PDA J Pharm Sci Technol; 2008; 62(4):256-63. PubMed ID: 19174954
[TBL] [Abstract][Full Text] [Related]
29. Development of alginate-reinforced chitosan nanoparticles utilizing W/O nanoemulsification/internal crosslinking technique for transdermal delivery of rabeprazole.
Ahmed TA; El-Say KM
Life Sci; 2014 Aug; 110(1):35-43. PubMed ID: 24997393
[TBL] [Abstract][Full Text] [Related]
30. A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Zhao JH; Fu JH; Wang SM; Su CH; Shan Y; Kong SJ; Wang Y; Lu WL; Zhang H; Zhang S; Li L; Zhang EH; Wang L; Pei QL; Wang JC; Zhang X; Zhang Q
Int J Pharm; 2007 Jun; 337(1-2):88-101. PubMed ID: 17267147
[TBL] [Abstract][Full Text] [Related]
31. Formulation study of a patch containing propranolol by design of experiments.
Cilurzo F; Minghetti P; Gennari CG; Casiraghi A; Selmin F; Montanari L
Drug Dev Ind Pharm; 2014 Jan; 40(1):17-22. PubMed ID: 23301830
[TBL] [Abstract][Full Text] [Related]
32. Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol.
Zhang Y; Zhi Z; Li X; Gao J; Song Y
Int J Pharm; 2013 Sep; 454(1):403-11. PubMed ID: 23850816
[TBL] [Abstract][Full Text] [Related]
33. Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery.
Aboud HM; El Komy MH; Ali AA; El Menshawe SF; Abd Elbary A
AAPS PharmSciTech; 2016 Dec; 17(6):1353-1365. PubMed ID: 26743643
[TBL] [Abstract][Full Text] [Related]
34. Co-rotating twin screw process for continuous manufacturing of solid crystal suspension: A promising strategy to enhance the solubility, permeation and oral bioavailability of Carvedilol.
Navti PD; Fernandes G; Soman S; Nikam AN; Kulkarni S; Birangal SR; Dhas N; Shenoy GG; Rao V; Koteshwara KB; Mutalik S
F1000Res; 2023; 12():1438. PubMed ID: 38778814
[No Abstract] [Full Text] [Related]
35. Optimization of self-nanoemulsifying systems for the enhancement of in vivo hypoglycemic efficacy of glimepiride transdermal patches.
Ahmed OA; Afouna MI; El-Say KM; Abdel-Naim AB; Khedr A; Banjar ZM
Expert Opin Drug Deliv; 2014 Jul; 11(7):1005-13. PubMed ID: 24702435
[TBL] [Abstract][Full Text] [Related]
36. Development of mucoadhesive patches for buccal administration of carvedilol.
Vishnu YV; Chandrasekhar K; Ramesh G; Rao YM
Curr Drug Deliv; 2007 Jan; 4(1):27-39. PubMed ID: 17269915
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
38. Development of matrix-type transdermal delivery of lornoxicam: in vitro evaluation and pharmacodynamic and pharmacokinetic studies in albino rats.
Baviskar DT; Parik VB; Jain DJ
PDA J Pharm Sci Technol; 2013; 67(1):9-22. PubMed ID: 23385560
[TBL] [Abstract][Full Text] [Related]
39. Transdermal ethosomal gel nanocarriers; a promising strategy for enhancement of anti-hypertensive effect of carvedilol.
Ibrahim TM; Abdallah MH; El-Megrab NA; El-Nahas HM
J Liposome Res; 2019 Sep; 29(3):215-228. PubMed ID: 30272506
[TBL] [Abstract][Full Text] [Related]
40. Silicone adhesive, a better matrix for tolterodine patches-a research based on in vitro/in vivo studies.
Liu J; Wang Z; Liu C; Xi H; Li C; Chen Y; Sun L; Mu L; Fang L
Drug Dev Ind Pharm; 2012 Aug; 38(8):1008-14. PubMed ID: 22126709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
